Camzyos

(Mavacamten)

Camzyos

Drug updated on 11/15/2023

Dosage FormCapsule (oral; 2.5 mg, 5 mg, 10 mg, 15 mg)
Drug ClassCardiac myosin inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.